Additive antitumor effect of arsenic trioxide with exposure to ionizing radiation to human acute promyelocytic leukemia HL‑60 cells

Oncol Rep. 2024 Aug;52(2):109. doi: 10.3892/or.2024.8768. Epub 2024 Jul 4.

Abstract

Arsenic trioxide (ATO) is expected to be a chemical drug with antitumor activity against acute promyelocytic leukemia (APL), a type of acute myeloid leukemia. In Japan, its antitumor effects were confirmed in clinical trials for APL, and it has been approved in various countries around the world. However, there have been no reports on ATO's antitumor effects on radioresistant leukemia cells, which can be developed during radiotherapy and in combination with therapeutic radiation beams. The present study sought to clarify the antitumor effect of ATO on APL cells with radiation resistance and determine its efficacy when combined with ionizing radiation (IR). The radiation‑resistant HL60 (Res‑HL60) cell line was generated by subjecting the native cells to 4‑Gy irradiation every week for 4 weeks. The half‑maximal inhibitory concentration (IC50) for cell proliferation by ATO on native cell was 0.87 µM (R2=0.67), while the IC50 for cell proliferation by ATO on Res‑HL60 was 2.24 µM (R2=0.91). IR exposure increased the sub‑G1 and G2/M phase ratios in both cell lines. The addition of ATO resulted in a higher population of G2/M after 24 h rather than 48 h. When the rate of change in the sub‑G1 phase was examined in greater detail, the sub‑G1 phase in both control cells without ATO significantly increased by exposure to IR at 24 h, but only under the condition of 2 Gy irradiation, it had continued to increase at 48 h. Res‑HL60 supplemented with ATO showed a higher rate of sub‑G1 change at 24 h; however, 2 Gy irradiation resulted in a decrease compared with the control. There was a significant increase in the ratio of the G2/M phase in cells after incubation with ATO for 24 h, and exposure to 2 Gy irradiation caused an even greater increase. To determine whether the inhibition of cell proliferation and cell cycle disruptions is related to reactive oxygen species (ROS) activity, intracellular ROS levels were measured with a flow cytometric assay. Although the ROS levels of Res‑HL60 were higher than those of native cells in the absence of irradiation, they did not change after 0.5 or 2 Gy irradiation. Furthermore, adding ATO to Res‑HL60 reduced intracellular ROS levels. These findings provide important information that radioresistant leukemia cells respond differently to the antitumor effect of ATO and the combined effect of IR.

Keywords: HL‑60; arsenic trioxide; cell cycle distribution; radioresistant leukemia; reactive oxygen species.

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Apoptosis / drug effects
  • Apoptosis / radiation effects
  • Arsenic Trioxide* / pharmacology
  • Arsenicals* / pharmacology
  • Cell Proliferation* / drug effects
  • Cell Proliferation* / radiation effects
  • HL-60 Cells
  • Humans
  • Leukemia, Promyelocytic, Acute* / drug therapy
  • Leukemia, Promyelocytic, Acute* / pathology
  • Leukemia, Promyelocytic, Acute* / radiotherapy
  • Oxides* / pharmacology
  • Radiation Tolerance / drug effects
  • Radiation, Ionizing*
  • Reactive Oxygen Species / metabolism

Substances

  • Arsenic Trioxide
  • Arsenicals
  • Oxides
  • Antineoplastic Agents
  • Reactive Oxygen Species

Grants and funding

This work was supported by JSPS KAKENHI, Grants-in-Aid for Scientific Research (B) (grant no. 21H02861 to SM), Fund for the Promotion of Joint International Research (Fostering Joint International Research; grant no. 17KK0181 to SM), and Grant-in-Aid for Challenging Research (Exploratory) (grant no. 19K22731 to SM). The Takeda Science Foundation (2022, to SM) also provided support. The funders had no involvement in the study design, data collection and analysis, decision to publish or manuscript preparation.